Oppenheimer Lowers Price Target on Gilead Sciences Following Fourth Quarter Earnings Report
In light of Gilead Sciences’ recent fourth quarter earnings report and investor update, Oppenheimer has adjusted its outlook on the biopharmaceutical company. The firm has revised its price target on Gilead’s stock, lowering it to $105 from the previous $115 while maintaining an Outperform rating.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
